Treatment of adult hyper-IgD syndrome with canakinumab
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 3(2015), 5 vom: 01. Sept., Seite 817-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Curtis, Casey D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.07.2016 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2015.05.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250364670 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250364670 | ||
| 003 | DE-627 | ||
| 005 | 20231224155556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2015.05.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0834.xml |
| 035 | |a (DE-627)NLM250364670 | ||
| 035 | |a (NLM)26116953 | ||
| 035 | |a (PII)S2213-2198(15)00265-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Curtis, Casey D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of adult hyper-IgD syndrome with canakinumab |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2016 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 650 | 7 | |a canakinumab |2 NLM | |
| 650 | 7 | |a 37CQ2C7X93 |2 NLM | |
| 650 | 7 | |a Phosphotransferases (Alcohol Group Acceptor) |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a mevalonate kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.36 |2 NLM | |
| 700 | 1 | |a Fox, Charity C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 3(2015), 5 vom: 01. Sept., Seite 817-8 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2015 |g number:5 |g day:01 |g month:09 |g pages:817-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2015.05.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2015 |e 5 |b 01 |c 09 |h 817-8 | ||